JC04 Rec'd PCT/PTO 25 JUL 2005

JC04 Rec'd PC

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment; Commissioner for Patents; P.O. Box 1450; Alexandria, Virginia 22313-1450 on

PATENT

Bornie S. Doll

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:

Magnus Ingelman-Sundberg et al

Paper No.

Serial No.:

10/532,014

Group Art Unit:

Filing Date:

April 20, 2005

Examiner:

For:

The Use of Cytochrome P450 Enzyme CYP2W1 as a Drug Target for Cancer Therapy

Papillomavirus

TIFICATE OF MAILING

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. §§ 1.56 and 1.97-1.98, Applicants cite the references listed on the attached Form PTO-1449. Copies of the non-U.S. patent references are enclosed.

Since the present statement is submitted before the mailing of a first Office Action on the merits, no statement or fee under 37 C.F.R. §1.97 is required (37 C.F.R. §1.97(b)(1)).

Please charge any fee required in connection with this Statement to Deposit Account 04-1133.

Respectfully submitted,

By:

Holly D. Kozlowski

Registration No. 30,468

Attorney for Applicant(s)

DINSMORE & SHOHL LLP

1900 Chemed Center

255 East Fifth Street

Cincinnati, Ohio 45202

(513) 977-8568

O FORM	1 4/92									Page 1	of 1
RM PTC ST OF PA R APPLI SCLOSU	D-1449 ATENT ICANT	SINF	ORM	IATIC	ATTO R	N5 25		ATTY. DOCKET 25401-40 SERIAL NO. 10/532,014 APPLICANT Magnus Ingelman-Sundberg et al			
VITED ST	ATESIE	TTERS	PATE	NT	W.		- EMP	7			
VITED 31	ATES LETTERS PATENT DOCUMENT NUMBER						ADV	DATE	NAME	CLASS	SUB
	DOCUMENT NUMBER							DATE	NAME	0221.00	CLASS
							<u> </u>				
						<u> </u>	<u> </u>				
_						<u> </u>	-				
_											
						1					
II	<u>l</u>	<u> </u>			L						
₁₁	FORE	IGN PA	TENT	DOCE	JMEN	TS		1	T		1
	DOCU	MENT	NUMBI	ER				DATE	COUNTRY	CLASS	SUB CLASS
aa	wo	01	5	8	4	5	5	Aug. 16, 2001	PCT		CLASS
	ļ	<u> </u>	ļ	ļ	<u> </u>						
_	╂	-		+							
_	1	<u> </u>	 								
OTHER AF	T (INCL	JDING .	AUTHO	OR, TIT	ΓLE, D	ATE, F	ERTIN	IENT PAGES, ETC.)			
ab	RT (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) Magnus Ingelman-Sundberg, "Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms", Naunyn-Schmiedeberg's Arch Pharmacol, (2004) 369:89-104.										
ac	Youssef Joundaidi et al, "Frequent, Moderate-Dose Cyclophosphamide Administration Improves the Efficacy of Cytochrome P-450/Cytochrome P-450 Reductase-based Cancer Gene Therapy", <i>Cancer Research</i> , 61, June 1, 2001, pp. 4437-444.										
ad	Julie D. Thompson et al, "The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignm									e alignment	
	aided by quality analysis tools", <i>Nucleic Acids Research</i> , 1997, Vol. 25, No. 24, pp. 4876-4882. David J. Waxman et al, "Cytochrome P450-Based Cancer Gene Therapy: Recent Advances and Future Prospects",										
ae	David J. Waxman et al, "Cytochrome P450-Based Cancer Gene Therapy: Recent Advances and Future Prospects", Drug Metabolism Reviews, 31(2), 503-522 (1999).										riospecto ,
af	Straus	sberg, I	R., EM	ßL D	atabas	se, Ac	cessio	n No. Q8TAV3, J	une 1, 2002.		
ah		STN Database, CAPLUS, Vol. 126:221319 (1997).									
ai ai	STN Database, CAPLUS, Vol. 125:292401 (1996). Biosis Database, Accession No. PREV200200495954 (2002).										
ak	Magnus Ingelman-Sundberg, "Genetic susceptibility to adverse effects of drugs and environmental toxicants", Mutation										
al	Research, 482 (2001), pp. 11-19. Daniel W. Nebert et al, "Clinical importance of the cytochromes P450", The Lancet, Vol. 360, October 12, 2002, pp.										
	1155-	1162.						· · · · · · · · · · · · · · · · · · ·			

	-		<u></u>					· · · · · · · · · · · · · · · · · · ·			
	 								W-7		
	1										
_	+	-									